Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT06377566
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
BV-AVD-R Treatment Children Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06201507
- Locations
- 🇨🇳
Duan Yanlong, Beijing, China
CD30 Imaging in Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 20
- Registration Number
- NCT06186986
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05922904
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BendamustineDrug: Brentuximab VedotinDrug: CarboplatinProcedure: Computed TomographyDrug: EtoposideDrug: GemcitabineDrug: IfosfamideDrug: Pegylated Liposomal Doxorubicin HydrochlorideProcedure: Positron Emission TomographyBiological: PembrolizumabRadiation: Radiation TherapyOther: Transplant ConditioningDrug: Vinorelbine
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05711628
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Conditions
- Interventions
- Procedure: Biospecimen CollectionBiological: Bleomycin SulfateProcedure: Computed TomographyDrug: Brentuximab VedotinDrug: DacarbazineDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingDrug: EtoposideProcedure: Positron Emission TomographyDrug: Etoposide PhosphateOther: Questionnaire AdministrationBiological: NivolumabDrug: Vinblastine SulfateRadiation: Involved-site Radiation TherapyDrug: PrednisoloneDrug: PrednisoneDrug: Procarbazine HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1875
- Registration Number
- NCT05675410
- Locations
- 🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT05673785
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, China
🇨🇳The First Affiliated Hospital of Zhejiang University school of medicine, Hangzhou, China
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 8
- Registration Number
- NCT05481437
- Locations
- 🇯🇵
Takeda selected site, Tokyo, Japan
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 10
- Registration Number
- NCT05442554
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 10
- Registration Number
- NCT05414500
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.